820231-27-4

Usage

InChI:InChI=1/C12H19N3O2S/c1-12(2,3)17-11(16)14-7-4-5-8-9(6-7)18-10(13)15-8/h7H,4-6H2,1-3H3,(H2,13,15)(H,14,16)

Upstream product

• 34619-03-9 tert-butyldicarbonate 
• 106006-83-1 2,6-diamino-4,5,6,7-tetrahydro-benzthiazole 
• 179321-49-4 N-(tert-butoxycarbonyl)-4-aminocyclohexanone 
• 1073632-93-5 tert-butyl (3-bromo-4- oxocyclohexyl)carbamate 
• 17356-08-0 thiourea 

Downstream Products

• 1251009-79-6 tert-butyl (2-bromo-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)carbamate 
• 1379295-90-5 2-bromo-4,5,6,7-tetrahydro-benzothiazol-6-ylamine 

Relevant academic research and scientific papers

SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS

The present invention relates to heterocyclyl compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and th

THIAZOLIMINE COMPOUND AND OXAZOLIMINE COMPOUND

A compound represented by the formula (1): (wherein X represents sulfur or oxygen; R1 and R2 each represents a group represented by the formula -Y3-Z, etc.; Y3 represents a single bond or (un)substituted alkylene; Y1 and Y2 each represents (un)substituted alkylene; Z represents hydrogen, an (un)saturated monocyclic heterocyclic group, etc.; M represents carboxy, etc.; Q represents o-phenylene, etc.; and A represents an (un)saturated monocyclic hydrocarbon group, etc.), a prodrug thereof, or a pharmaceutically acceptable salt of either. They are compounds having chymase inhibitory activity and useful as a therapeutic agent for hypertension, cardiac failure, etc.